New drug cocktail aims to tame metastatic prostate cancer

NCT ID NCT05367440

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and how well the drugs work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD5305 (a targeted cancer drug) combined with hormone therapies (enzalutamide, abiraterone acetate, darolutamide, or apalutamide)
What this could lead to: If successful, this could point toward a new combination treatment that helps control metastatic prostate cancer for longer.
What could go wrong: This is an early-phase trial with only 174 participants, so results may not apply to all patients. The drug combinations could cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Research Site

Detroit, Michigan, 48201, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

Syracuse, New York, 13210, United States
Research Site

Myrtle Beach, South Carolina, 29572, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Houston, Texas, 77094, United States
Research Site

Camperdown, 2050, Australia
Research Site

Darlinghurst, 2010, Australia
Research Site

East Melbourne, 3002, Australia
Research Site

Heidelberg, 3084, Australia
Research Site

Melbourne, 3004, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Candiolo, 10060, Italy
Research Site

Milan, 20133, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Padova, 35128, Italy
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Glasgow, G12 0YN, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Plymouth, PL6 8DH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.